Jushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSH), a vertically integrated multi-state cannabis operator headquartered in Boca Raton, Florida, announced on November 3, 2026 that it has received registrations from the U.S. Drug Enforcement Administration for certain of its state-licensed medical marijuana operations. The registrations form part of an initial federal issuance to qualifying medical marijuana businesses following a rescheduling order. The development represents a milestone for Jushi as it pursues alignment between its state-level cannabis licences and the federal regulatory framework.

Key Points

  • Jushi Holdings Inc. (CSE: JUSH / OTCQX: JUSH) is a vertically integrated, multi-state cannabis operator focused on branded cannabis assets
  • The company has received DEA registrations covering certain state-licensed medical marijuana operations as part of an initial federal issuance to qualifying businesses
  • The registrations follow the Attorney General's April 2026 order rescheduling qualifying state-licensed medical marijuana to Schedule III under the Controlled Substances Act
  • Jushi had previously announced submission of its DEA registration applications on May 28, 2026

DEA Registrations Stem from April 2026 Federal Rescheduling Order

The DEA registrations Jushi received are a direct result of the Attorney General's April 2026 order, which rescheduled qualifying state-licensed medical marijuana to Schedule III under the Controlled Substances Act. That order also established a federal regulatory framework for eligible operators. Jushi, which builds its multi-state portfolio through acquisitions, distressed workouts, and competitive licence applications, submitted its DEA registration applications on May 28, 2026, as the company previously disclosed. The receipt of registrations completes this initial application process for the company's covered medical operations.

Jushi's Multi-State Medical Cannabis Operations and Federal Standing

Jushi describes itself as a vertically integrated cannabis company led by what it characterises as an industry-leading management team, operating across multiple U.S. states. The company focuses on delivering branded cannabis products across all levels of the cannabis ecosystem, including to medical patients. Chief Executive Officer Jim Cacioppo stated in the release that receiving DEA registrations "represents an important milestone for Jushi and the medical patients we serve," and characterised the development as "an important step toward greater alignment between state and federal regulation." The company did not disclose which specific state operations are covered by the registrations.

Broader Industry Context Acknowledged by Jushi's Leadership

In the announcement, CEO Jim Cacioppo acknowledged the role of the Trump Administration and the DEA in what he described as "advancing meaningful cannabis reform and recognising state-licensed medical cannabis operators." The release frames the federal registrations as contributing to a "more consistent regulatory framework for the industry," reflecting Jushi's view that Schedule III status creates a new operating environment for compliant multi-state medical cannabis businesses. The company did not disclose any specific financial, operational, or revenue figures in connection with the receipt of these registrations.